Similar articles

• Very limited data in the Global Burden of Disease Study 2019 to estimate the prevalence of osteoarthritis in 204 countries over 30 years: comment on the article by Long et al.

  Chen Q, Maher CG, Machado GC. Chen Q, et al. Arthritis Rheumatol. 2022 Aug;74(8):1455-1456. doi: 10.1002/art.42136. Epub 2022 Jun 28. Arthritis Rheumatol. 2022. PMID: 35373923 No abstract available.
• Response to the letter to editor by Chen et al. regarding: Burden of osteoarthritis in India and its states, 1990-2019: findings from the Global Burden of Disease Study 2019.

  Singh A, Antony B. Singh A, et al. Osteoarthritis Cartilage. 2022 Oct;30(10):1413-1414. doi: 10.1016/j.joca.2022.07.009. Epub 2022 Aug 12. Osteoarthritis Cartilage. 2022. PMID: 35964849 No abstract available.
• Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.

  Conn DL. Conn DL. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622-3; author reply 1623-4. doi: 10.1002/acr.21809. Arthritis Care Res (Hoboken). 2012. PMID: 23024030 No abstract available.
• Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.

  Graudal N, Jürgens G. Graudal N, et al. Arthritis Care Res (Hoboken). 2013 May;65(5):832. doi: 10.1002/acr.21873. Arthritis Care Res (Hoboken). 2013. PMID: 23097263 No abstract available.
• Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al.

  Berthelot JM, Maugars Y, Prost A. Berthelot JM, et al. Arthritis Rheum. 1997 Jan;40(1):193-4; author reply 195-6. doi: 10.1002/art.1780400129. Arthritis Rheum. 1997. PMID: 9008619 Review. No abstract available.